NEUP

2.3501.29%
SP

Spyridon Papapetropoulos

Interim CEO & Executive Director

Dr. Spyridon Papapetropoulos, also known as Spyros, M. D., Ph. D., is Chief Development Officer & Strategic Advisor of Razor, Inc. He served as Chief Executive Officer at Neuphoria Therapeutics Inc. (formerly known as Bionomics Limited) from January 05, 2023 until December 31, 2025 and served as its President since January 05, 2023 until 2026 and serves as its Executive Director since January 05, 2023 and also serves as its Interim Chief Executive Officer since January 01, 2026. He served as Member of Scientific Advisory Board at Vigil Neuroscience, Inc since January 04, 2023 until October 2023. He served as Chief Medical Officer of Vigil Neuroscience, Inc since September 2020 until January 04, 2023. He served as Board of Director at Lipocine Inc. since April 2022 until April 16, 2026 and served as its Lead Independent Director and Chairman of the Board since November 2022 until April 16, 2026. He had been Independent Director at Adamas Pharmaceuticals, Inc. since November 2020 until November 24, 2021. He is the Founder and President of Encephalos Life Sciences LLC. Dr. Papapetropoulos served as Senior Vice President and Head of Clinical Development at ACADIA Pharmaceuticals Inc. since 2020 until 2020. He had been an Executive Vice President of Research & Development and Chief Medical Officer of Cavion LLC since August 15, 2017 until April 2019 and had been its Head of Research & Development since December 7, 2017 until 2019. Dr. Papapetropoulos leads Cavions research and development organization to advance therapies based on the T-type calcium channel (Cav3) platform. He has extensive academic, biopharmaceutical and digital health exposure. He served as a Vice Presidentof Global Specialty Development, Neurodegenerative Diseases, Movement Disorders and Clinical Trial Innovation at Teva Pharmaceutical Industries Ltd. Prior to Teva, he managed neuroscience research and medical affairs programs at Pfizer Inc., Allergan Inc. and Biogen Idec Inc. Dr. Papapetropoulos has overseen a wide spectrum of pharmaceutical development programs from regulatory filing to new product launch. Dr. Papapetropoulos served as a Consultant of Massachusetts General Hospital and voluntary Professor of Neurology with the University of Miami, Miller School of Medicine. He received his MD and PhD in Greece from University of Patras, School of Health Sciences, Faculty of Medicine (Greece) and received an M. D. from Semmelweis University in Budapest, Hungary.

Positions